GlassScriptPrepare for your visit
Rodney S Daniel
Rheumatology · Oldsmar, FL · NPI 1912094822
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$480,886.34
in general payments reported to CMS, 2019-2025 · $145K in 2025
The $145K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Who reported paying
General payments only, top 6 by amount.
- Genzyme Corporation $185,123.14
- Abbvie INC. $121,173.72
- Boehringer Ingelheim Pharmaceuticals, INC. $99,019.68
- Astrazeneca Pharmaceuticals LP $10,670.57
- Alexion Pharmaceuticals, INC. $10,637.38
- Fresenius Kabi USA, LLC $9,166.17
Drugs and devices associated with these payments
Kevzara Rinvoq Ofev Skyrizi Saphnelo Strensiq Pemgarda Cosentyx Xeljanz Purified Cortrophin Gel Tremfya Idacio
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Rodney Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/40909/rodney-s-daniel